Skip to content

An observational study to evaluate xueshuantong for injection (lyophilized) in the treatment of ischemic stroke

An Observational Study to Evaluate Xueshuantong Injection (Lyophilized) in the Treatment of Ischemic Stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200060658
Enrollment
Unknown
Registered
2022-06-06
Start date
2022-06-15
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke

Interventions

Sponsors

Jiangsu Province Hospital on Integration of Chinese and Western Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Western medical diagnostic of ischemic stroke - based on the diagnosis code or diagnostic name of the disease at the time of hospitalization or outpatient consultation, combined with other treatment of patients with comprehensive analysis; if no Western medical diagnostic criteria are available, patients who have had a stroke and meet the diagnostic criteria of blood stasis syndrome in traditional Chinese medicine patients can be enrolled.

Exclusion criteria

Exclusion criteria: 1. Known allergy to Xueshuantong injection (lyophilized); 2. known allergy to ginseng and notoginseng; 3. In the acute phase of bleeding disorders;

Design outcomes

Primary

MeasureTime frame
Changes in National Institutes of Health Stroke Scale (NIHSS) scores before and after treatment;Change in modified Rankin scale score (mRS score) before and after treatment;Occurrence of adverse events after treatment;

Secondary

MeasureTime frame
Recurrence of ischemic stroke;

Countries

China

Contacts

Public ContactHongquan Liu
57142566@qq.com+86 13812345678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026